Viking Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2014 to 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Viking Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2014 to 2024.
  • Viking Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$35.4M, a 43.9% decline year-over-year.
  • Viking Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$110M, a 28% decline year-over-year.
  • Viking Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$110M, a 28% decline from 2023.
  • Viking Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$85.9M, a 24.7% decline from 2022.
  • Viking Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$68.9M, a 25.2% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.